Pfizer CEO says people will 'likely' need third jab within a year and could need annual shots

Initial data has shown that the vaccines retain most of their effectiveness for at least six months, though for how much longer has not been determined.

People could need a booster dose of a COVID-19 vaccine within 12 months of getting fully vaccinated, according to Pfizer CEO Albert Bourla.

People could need a booster dose of a COVID-19 vaccine within 12 months of getting fully vaccinated, according to Pfizer CEO Albert Bourla. Source: NurPhoto

The Biden administration is preparing for the possibility that people will need a third dose of the Pfizer COVID-19 vaccine within a year of receiving their initial jab.

Pfizer Inc Chief Executive Albert Bourla said people will “likely” need a third booster dose of COVID-19 vaccines within 12 months and could need annual shots, in comments made on 1 April and reported by CNBC overnight.

While the duration of immunity after vaccination is being studied, booster vaccines could be needed, David Kessler, chief science officer for President Joe Biden's COVID-19 response task force told a congressional committee meeting.

"The current thinking is those who are more vulnerable will have to go first," he said.
Initial data has shown that vaccines from Moderna Inc and partners Pfizer Inc and BioNTech SE retain most of their effectiveness for at least six months, though for how much longer has not been determined.

Even if that protection lasts far longer than six months, experts have said that rapidly spreading variants of the coronavirus and others that may emerge could lead to the need for regular booster shots similar to annual flu shots.

The United States is also tracking infections in people who have been fully vaccinated, Rochelle Walensky, director of the US Centres of Disease Control and Prevention told the House subcommittee hearing.
Of 77 million people vaccinated in the United States, there have been 5,800 such breakthrough infections, Walensky said, including 396 people who required hospitalisation and 74 who died.

Ms Walensky said some of these infections have occurred because the vaccinated person did not mount a strong immune response. But the concern is that in some cases, they are occurring in people infected by more contagious virus variants.

Earlier this month, Pfizer and partner BioNTech said their vaccine was around 91 per cent effective in preventing COVID-19, citing updated trial data that included more than 12,000 people fully inoculated for at least six months.


Share
2 min read

Published

Updated

Source: Reuters, SBS


Share this with family and friends


Get SBS News daily and direct to your Inbox

Sign up now for the latest news from Australia and around the world direct to your inbox.

By subscribing, you agree to SBS’s terms of service and privacy policy including receiving email updates from SBS.

Download our apps
SBS News
SBS Audio
SBS On Demand

Listen to our podcasts
An overview of the day's top stories from SBS News
Interviews and feature reports from SBS News
Your daily ten minute finance and business news wrap with SBS Finance Editor Ricardo Gonçalves.
A daily five minute news wrap for English learners and people with disability
Get the latest with our News podcasts on your favourite podcast apps.

Watch on SBS
SBS World News

SBS World News

Take a global view with Australia's most comprehensive world news service
Watch the latest news videos from Australia and across the world